Bio-Techne Corporation logo TECH - Bio-Techne Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 13
HOLD 13
SELL 0
STRONG
SELL 0
| PRICE TARGET: $66.44 DETAILS
HIGH: $79.00
LOW: $50.00
MEDIAN: $73.00
CONSENSUS: $66.44
DOWNSIDE: 6.82%

Stock News

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.

Jul 08, 2026 02:30 AM • prnewswire.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)

BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Jul 06, 2026 08:17 AM • globenewswire.com
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.

Jul 02, 2026 01:31 AM • globenewswire.com (Hide legal announcements)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)

BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Jun 30, 2026 09:13 AM • globenewswire.com
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH

Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

Jun 29, 2026 12:21 PM • businesswire.com (Hide legal announcements)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)

NEW YORK, June 26, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH ) related to its sale to Merck KGaA.

Jun 26, 2026 10:24 AM • prnewswire.com (Hide legal announcements)
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

MILWAUKEE, June 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Jun 25, 2026 06:00 AM • prnewswire.com (Hide legal announcements)
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.

Jun 25, 2026 03:48 AM • businesswire.com
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing U.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journey Would deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chain Would add complementary strengths across research, bioprocessing and advanced therapeutics, bolstering the offering of Merck KGaA, Darmstadt, Germany, in next-generation biology Synergistic platform would broaden offerings, accelerate innovation pipeline of Merck KGaA, Darmstadt, Germany, and increase Bio-Techne's geographic and omnichannel access for customers Merck KGaA, Darmstadt, Germany, expects annual cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closing DARMSTADT, Germany and MINNEAPOLIS, June 25, 2026 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price. The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through development, testing and commercial manufacturing.

Jun 25, 2026 02:10 AM • prnewswire.com

Price Targets